Brooklyn Investment Group acquired a new position in Willis Towers Watson Public Limited (NASDAQ:WTW – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 558 shares of the company’s stock, valued at approximately $164,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new stake in Willis Towers Watson Public during the third quarter valued at about $27,000. American National Bank bought a new stake in shares of Willis Towers Watson Public in the second quarter worth about $36,000. Ashton Thomas Securities LLC purchased a new stake in Willis Towers Watson Public in the third quarter worth about $41,000. New Millennium Group LLC purchased a new stake in Willis Towers Watson Public in the second quarter worth about $54,000. Finally, LRI Investments LLC purchased a new stake in Willis Towers Watson Public in the first quarter worth about $58,000. Hedge funds and other institutional investors own 93.09% of the company’s stock.
Willis Towers Watson Public Trading Up 1.3 %
NASDAQ:WTW opened at $320.86 on Thursday. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.70. Willis Towers Watson Public Limited has a 12 month low of $234.01 and a 12 month high of $321.63. The company has a market cap of $32.32 billion, a PE ratio of -44.07, a price-to-earnings-growth ratio of 1.97 and a beta of 0.73. The company has a 50 day simple moving average of $300.03 and a two-hundred day simple moving average of $280.43.
Analysts Set New Price Targets
Several analysts have commented on the stock. Keefe, Bruyette & Woods raised their price objective on shares of Willis Towers Watson Public from $352.00 to $359.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Truist Financial lifted their target price on shares of Willis Towers Watson Public from $335.00 to $365.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Roth Mkm lifted their target price on shares of Willis Towers Watson Public from $315.00 to $345.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Wells Fargo & Company lifted their target price on shares of Willis Towers Watson Public from $334.00 to $340.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Finally, UBS Group upgraded shares of Willis Towers Watson Public to a “hold” rating in a report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Willis Towers Watson Public presently has a consensus rating of “Hold” and an average target price of $313.87.
View Our Latest Analysis on Willis Towers Watson Public
Willis Towers Watson Public Profile
Willis Towers Watson Public Limited Company operates as an advisory, broking, and solutions company worldwide. It operates through two segments: Health, Wealth & Career and Risk & Broking. The company offers strategy and design consulting, plan management service and support, broking and administration services for health, wellbeing, and other group benefit program, including medical, dental, disability, life, voluntary benefits and other coverages; actuarial support, plan design, and administrative services for pension and retirement savings plans; retirement consulting services and solutions; and integrated solutions that consists of investment discretionary management, pension administration, core actuarial, and communication and change management assistance services.
Further Reading
- Five stocks we like better than Willis Towers Watson Public
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is the NASDAQ Stock Exchange?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Trading Halts Explained
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Willis Towers Watson Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Willis Towers Watson Public and related companies with MarketBeat.com's FREE daily email newsletter.